U.S. Markets open in 3 hrs 55 mins

How Healthcare Is Evolving & Sector Stocks To Watch

CORAL GABLES, FL / ACCESSWIRE / November 30,2018 / The Global Connected Healthcare Market was valued at USD $1,860.26 million in2017, and is expected to grow at a CAGR of 28.3% by 2025. This is according to new findings from Orian Research*. The report cites that the market is driven by increasing demandof quality healthcare services. North America expected to lead the Connected Healthcare Industry during the forecast period. The latest healthcare models,rise in government spending on automated systems in healthcare, and the adoption of skilled manpower is projected to propel the market growth.

Healthcare Stocks In Focus: Premier Health Group, Inc. (PHGRF) (PHGI), Teladoc (TDOC), Allscripts Healthcare Solutions, Inc. (MDRX) and Fate Therapeutics, Inc. (FATE).

There has been a growing increase in the use of smartphones by physicians leading to a practice of digital health. The global digital health market is expanding at a fast pace. This can be due, in part, to growing demand foradvanced healthcare information system and increasing support from government organizations.

Premier Health Group, Inc. (PHGRF) (PHGI)'s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and has plans to rapidly increase that number both domestically and internationally.

Premier Health Group, Inc. (PHGRF) (PHGI) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companiesand government officials in order to establish a framework for both patient and physician education. Furthermore, the Company is actively recruiting additional physicians for its existing clinics and a cannabis-focused physician that is licensed in Canada.

This move could prove to beand exciting one for Premier. The Canadian medical cannabis clinic market is estimated to be worth approximately $2.35 billion by 2025. With this in mind, the company said that it expects to provide additional updates on acquisitions in Q4-18 and Q1-19.

"With over 110,000 active patients in our clinic ecosystem, it is important that we provide them with the best possible information that allows them to make informed decisions about their personal and family's health. Providing our family physicians with the appropriate tools and knowledge to prescribe cannabis or with the ability to refer patients to a specialist within our clinics is a key outcome of this initiative," said Dr. Essam Hamza, CEO of Premier.

For More Information On Premier Health Group, Click Here

Teladoc (TDOC) provides virtual care options for clients and patients. This month, the company announced the launch of Best Doctors Specialty Pharmacy Services, the first virtual care solution designed to tackle rising prescription drug costs using advanced analytics and an expert medical opinion. This unique analytics-driven virtual care solution helps employers and plan sponsors identify members with complex conditions such as Crohn's disease, psoriasis, lupus, or rheumatoid arthritis, and then engages an expert clinical team to carefully review the diagnosis and treatment plan to ensure the right course of action for each patient.

The service is initiated through a data-driven process that proactively and anonymously identifies those within a population who are most likely to benefit from an expert review of their diagnoses, treatment plans, and prescriptions. Best Doctors clinical experts can view an entire population, evaluate a high-risk group, or even identify an individual who would benefit from an in-depth case review.

"We already know that Best Doctors services have life changing results for our plan members – over half that access Best Doctors end up seeing a change in diagnosis or treatment," said Brad Fedorchuk, Senior Vice-President, Group Customer Experience & Marketing, Great-West Life. "What makes this program so exciting is that we can now leverage the power of our claims data and data analytics to proactively bring theselifechanging services to our members that need them most, and at the same time, help our plan sponsors lower the cost of theirbenefit programs."

For More Information On Teladoc, Click Here

Allscripts Healthcare Solutions, Inc. (MDRX) is a company focused on healthcare information technology solutions that advance clinical, financial and operational results. Allscripts' solutions connect people, placesand data across an Open, Connected Community of Health™.

Earlier this month the company announcedVeradigm as the new branding for Allscripts' Payer & Life Sciences division.Veradigm provides data-driven health insights and analytic solutions designed to increase efficiency and help manage the cost of healthcare.Veradigm's customers include healthcare providers, the life science industry and insurers.

"Veradigm is committed to improving healthcare and affecting positive change for patients by delivering data-driven insights and the advanced tools needed to act on them," says Tom Langan, Chief Executive Officer ofVeradigm. "Delivering on that promise requires next-generation solutions that can make an impact from the point of care to everyday life. That is exactly whatVeradigm was created to do."

Since November 20, shares of Allscripts have climbed from lows of $9.41 to as high as $10.32 this week.

For More Information On Allscripts, Click Here

Fate Therapeutics, Inc. (FATE) is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. This morning the company announced that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug Application for FT500, the Company's universal, off-the-shelf natural killer cell product candidate derived from a clonal master induced pluripotent stem cell line. The clinical trial of FT500 is expected to be the first-ever clinical investigation in the U.S. of an iPSC-derived cell product.

The Company plans to initiate first-in-human clinical testing of FT500 in combination with checkpoint inhibitor therapy for the treatment of advanced solid tumors. This study is expected to evaluate the safety and tolerability of multiple doses of FT500, in multiple dosing cycles with nivolumab, pembrolizumab oratezolizumab, in subjects that have progressed or failed on checkpoint inhibitor therapy.

Shares of Fate rose to highs of $15.25 just after market close on Thursday.

For More Information On Fate, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

*Orian Research Report: https://www.marketwatch.com/press-release/connected-healthcare-industry-2018-market-driven-by-increasing-demand-of-quality-healthcare-services-2018-11-28

Contact Information:

news@stockprice.com

SOURCE: StockPrice.com